Cargando…

Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies

Detalles Bibliográficos
Autores principales:	D'Amico, Emanuele, Zanghì, Aurora, Avolio, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504382/ https://www.ncbi.nlm.nih.gov/pubmed/34380893 http://dx.doi.org/10.4103/1673-5374.320985

Ejemplares similares

First‐line therapies in late‐onset multiple sclerosis: An Italian registry study
por: Zanghì, Aurora, et al.
Publicado: (2021)

Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications
por: Zanghì, Aurora, et al.
Publicado: (2022)

Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study
por: D’Amico, Emanuele, et al.
Publicado: (2023)

MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study
por: Zanghì, Aurora, et al.
Publicado: (2023)

Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register
por: D’Amico, Emanuele, et al.
Publicado: (2021)

Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study
por: Zanghì, Aurora, et al.
Publicado: (2022)

A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives
por: D’Amico, Emanuele, et al.
Publicado: (2016)

Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study
por: Zanghì, Aurora, et al.
Publicado: (2021)

Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review
por: Ciancio, Alessia, et al.
Publicado: (2023)

The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis
por: D’Amico, Emanuele, et al.
Publicado: (2019)

Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis
por: D’Amico, Emanuele, et al.
Publicado: (2021)

Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience
por: Zanghì, Aurora, et al.
Publicado: (2020)

Cryptic or Silent? The Known Unknowns, Unknown Knowns, and Unknown Unknowns of Secondary Metabolism
por: Hoskisson, Paul A., et al.
Publicado: (2020)

Autoimmune liver disease and multiple sclerosis: state of the art and future perspectives
por: Villani, Rosanna, et al.
Publicado: (2023)

Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience
por: Zanghì, Aurora, et al.
Publicado: (2020)

Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study
por: D'Amico, Emanuele, et al.
Publicado: (2020)

Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis
por: D’Amico, Emanuele, et al.
Publicado: (2022)

Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort
por: D'Amico, Emanuele, et al.
Publicado: (2019)

Disease X and other unknowns
por: Honigsbaum, Mark
Publicado: (2019)

Managing the financial risks of climate change and pandemics: What we know (and don't know)
por: Ranger, Nicola, et al.
Publicado: (2021)

Deaths due to Unknown Foodborne Agents
por: Frenzen, Paul D.
Publicado: (2004)

Fabry Disease: Switch from Enzyme Replacement Therapy to Oral Chaperone Migalastat: What Do We Know Today?
por: Perretta, Fernando, et al.
Publicado: (2023)

A scoping review of penile implant biofilms—what do we know and what remains unknown?
por: Leong, Joon Yau, et al.
Publicado: (2022)

What to know before forecasting the flu
por: Chakraborty, Prithwish, et al.
Publicado: (2018)

Therapeutic potential of trehalose in neurodegenerative diseases: the knowns and unknowns
por: Khalifeh, Masoomeh, et al.
Publicado: (2021)

Restless Legs Syndrome: Known Knowns and Known Unknowns
por: Antelmi, Elena, et al.
Publicado: (2022)

Intermittent Hypoxia and Respiratory Plasticity: The Good, the Bad, and the Unknown
por: Sheel, Andrew William
Publicado: (2023)

New era: prospects for managing cancer of unknown primary
por: Li, Yize, et al.
Publicado: (2023)

Disease-associated oligodendrocyte signatures in neurodegenerative disease: the known and unknown
por: Schuster, Kristen H., et al.
Publicado: (2023)

TAVR in 2017―What we know? What to expect?
por: Kourkoveli, Panagiota, et al.
Publicado: (2018)

Novel psychoactive substances: What educators need to know
por: Patterson, ZR, et al.
Publicado: (2016)

Five Medical Education Podcasts You Need to Know
por: Lomayesva, Natalie L., et al.
Publicado: (2020)

We know what we want, it’s just not there
por: Freundlich, Robert E., et al.
Publicado: (2021)

“Know Diabetes by Heart”: role of adipocyte-cardiomyocyte communications
por: Wang, Yajing, et al.
Publicado: (2021)

Health Literacy and People with Intellectual Disabilities: What We Know, What We Do Not Know, and What We Need: A Theoretical Discourse
por: Geukes, Cornelia, et al.
Publicado: (2019)

Beyond the Unknown: A Broad Framing for Preparedness for Emerging Infectious Threats
por: Christofferson, Rebecca C., et al.
Publicado: (2022)

Severe acute hepatitis of unknown origin in children: Clinical issues of concern
por: Fu, Hai-Jing, et al.
Publicado: (2023)

The Right to Know Is for Everyone
por: Hook, Gary E.R., et al.
Publicado: (2000)

Adult Guardianship in Korea: What Do Psychiatrists Need to Know?
por: Lim, Hyun Kook
Publicado: (2018)

What Do We Know About Remdesivir Drug Interactions?
por: Yang, Katherine
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5n3jtq7g9j7o6479fe207hmfkk